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In the United States, veterinary use of mupirocin is primarily limited to the treatment of canine pyoderma caused by methicillin-
resistant Staphylococcus pseudintermedius (MRSP). In this study, only 1 of 581 S. pseudintermedius isolates tested was resistant
to mupirocin and carried the high-level mupirocin resistance gene, ileS2, on a plasmid.
Staphylococcus pseudintermedius is the primary bacterial patho-gen isolated from canine pyoderma and also causes postsurgi-
cal infections in dogs (1, 2). Methicillin resistance and multidrug
resistance are increasing in S. pseudintermedius, thus limiting the
options for therapeutic treatment of canine skin infections (2).
Mupirocin is a bacteriostatic antibiotic that reversibly binds to
isoleucyl-tRNA synthetase to disrupt protein synthesis and is
widely used to eliminate nasal carriage of methicillin-resistant
Staphylococcus aureus (MRSA) in human MRSA carriers (3).
Mupirocin has been used on only a limited basis in veterinary
medicine but is approved in the United States for the treatment of
bacterial skin infections and superficial pyoderma in dogs (4).
In S. aureus, two levels of mupirocin resistance have been identi-
fied. Low-level mupirocin resistance occurs due to a point mutation
to the chromosomal ileS gene that encodes the native isoleucyl-tRNA
synthetase. The MIC for mupirocin for staphylococci carrying the
low-level resistance is 8 g/ml but 256 g/ml (5). Conversely,
high-levelmupirocin resistance (MICof512g/ml) is usually con-
ferred by the plasmid-borne ileS2, although a chromosomal location
of ileS2 has been reported (5). Recently, ileS2 plasmid-mediated
mupirocin resistance was found in a mupirocin-resistant, methicil-
lin-susceptible S. pseudintermedius strain isolated from a dog in
Croatia (6). The goal of the present study was to determine the
prevalence ofmupirocin resistance in S. pseudintermedius isolated
from patients presented to a veterinary hospital in Texas.
In this study, 581 isolates of S. pseudintermediuswere screened
for phenotypic low-level mupirocin resistance. Isolates were col-
lected from veterinary patients, predominantly dogs (n  446),
but also included isolates from cats (n  9). Some patients were
cultured at multiple sites and contributed more than one isolate,
and of these, 21 patients contributed more than two isolates. The
isolates included a historical collection of 403 isolates fromclinical
infections and contained both methicillin-resistant S. pseudinter-
medius (MRSP) isolates (n  153) and methicillin-susceptible S.
pseudintermedius (MSSP) isolates (n  250). The isolates from
clinical infections were collected from the following anatomic
sites: skin (n 96), external ear canal (n 31), wounds (n 79),
postoperative infections (n 33), urine or the urinary tract (n
87), and other sources (n 77). Additional isolates were collected
during a study of MRSP prevalence in canine patients without
clinical staphylococcal infection that presented for elective ortho-
pedic procedures. The MRSP prevalence study yielded 178 S.
pseudintermedius isolates (13 MRSP and 165 MSSP isolates) col-
lected from the nares or perineum of 129 dogs.
All isolates were presumptively identified as S. pseudinterme-
dius at the time of collection based onGram stain reaction, colony
color, and biochemical tests. Tests measured the ability of the
isolates to produce hemolysis on Trypticase soy agar supple-
mented with 5% sheep blood agar (blood agar plates) (BD Diag-
nostic Systems, Sparks, MD), to produce coagulase, to produce
catalase, and to grow on salt-mannitol agar. Isolates were also
tested for resistance to polymyxin B, ability to utilize trehalose,
and production of urease. At the time of initial collection, isolates
were tested for antimicrobial susceptibility using commercially
available systems (GPS card, Vitek; bioMérieux, Durham, NC;
COMPAN1F and COMPAN2F panels, Trek Sensititre; Trek Di-
agnostics, Cleveland, OH) and additionally tested for methicillin
resistance by oxacillin disk diffusion testing and PCR for the pres-
ence ofmecA. ThemecAPCRused a previously published protocol
with methicillin-resistant S. aureus (ATCC 33591) and methicil-
lin-susceptible S. aureus (ATCC 29213 or ATCC 25923) as posi-
tive and negative controls, respectively (7). Isolates were stored
frozen in 10% glycerol at 80°C in 96-well deep-well plates and
later inoculated aseptically using a 96-pin replicator ontoMueller-
Hinton agar (BD Diagnostic Systems) and onto Mueller-Hinton
agar supplemented with 8 g/ml mupirocin (Sigma-Aldrich, St.
Louis, MO) (here referred to as the mupirocin plate) to screen for
low-level resistance to mupirocin. Pseudomonas aeruginosa
(ATCC 27853) was used as a positive control for mupirocin resis-
tance (8). The bacterial concentrations were not standardized
prior to screening. Plates were incubated for 24 h at 37°C and then
examined.
Colonies were screened by PCR for the presence of the ileS2
gene using the previously published primers mupA and mupB to
amplify a 458-bp fragment of the ileS2 gene (9) and primers M1
andM2 to amplify a 237-bp fragment of the gene (Table 1) (10). A
total reaction volume of 50 l was used with the final concentra-
tions of reagents as follows: 2.5mMMgCl2, 0.2mMdeoxynucleo-
side triphosphates (dNTPs), 2.5 pmol of each primer, and 2.5 U
Taq polymerase per reaction (Lucigen, Middleton, WI). Three to
Received 28 December 2013 Returned for modification 21 January 2014
Accepted 23 January 2014
Published ahead of print 29 January 2014
Editor: A. B. Onderdonk
Address correspondence to Sara D. Lawhon, slawhon@cvm.tamu.edu.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.
doi:10.1128/JCM.03618-13
1250 jcm.asm.org Journal of Clinical Microbiology p. 1250–1252 April 2014 Volume 52 Number 4
 o
n
 Septem
ber 12, 2018 by guest
http://jcm.asm.org/
D
ow
nloaded from
 
five colonies isolated from the mupirocin plate were used for col-
ony PCR. Reactions were run in a 2720 thermal cycler (Applied
Biosystems, Grand Island, NY) using the following settings: 95°C
for 5 min; 35 cycles of 95°C for 30 s, 57°C for 30 s, and 72°C for 30
s, followed by 72°C for 7 min; and then a hold at 4°C. Negative
controls included water with no-template DNA and DNA from a
known mupirocin-sensitive, methicillin-sensitive S. aureus strain
(ATCC 29213). No positive control was available. The products
were then run on a 2% agarose gel for 2 h at 70 V, visualized with
GelRed (Phenix Research, Candler, NC), and compared to a
100-bp molecular size marker (Invitrogen, Grand Island, NY).
Plasmid purification was performed using the QIAprep Spin
Miniprep plasmid purification kit according to the manufactur-
er’s instructions (Qiagen, Valencia, CA). Samples were evaluated
for concentration and quality using a NanoDrop spectrometer
(Thermo Scientific,Waltham,MA) prior to PCR testing. PCRwas
used to evaluate the IS257-ileS2 spacer regions using a previously
published molecular classification system (11). The primers
IS257F, ileS2-5=, ileS2-3=, and IS257R (Table 1) were used in vari-
ous combinations as previously described under the following
conditions: 94°C for 5 min; 30 cycles of 94°C for 30 s, 60°C for 40
s, and 72°C for 60 s; then 72°C for 10 min; and then a hold at 4°C
(11). PCR was performed to identify the native ileS gene using the
primers ileS-F1 and ileS-R1 (Table 1) (6). Conditions for the ther-
mal cycler were as follows: 94°C for 5min; 30 cycles of 94°C for 30
s, 55°C for 30 s, 72°C for 60 s; then 72°C for 7 min; and a hold at
4°C.
PCR products were purified using either the QIAprep gel purifi-
cation kit (Qiagen, Valencia, CA) or the Zymoclean gel DNA recov-
ery kit (ZymoResearch, Irvine, CA) according to themanufacturers’
protocols. Purified PCR products were then cloned into pT7Blue
plasmid vector using the Novagen pT7Blue Perfectly Blunt cloning
kit (EMD Chemicals, Inc., Darmstadt, Germany) according to the
manufacturer’s protocol. Resultant plasmids containing the up-
stream IS257-ileS2 junction, the downstream ileS2-IS257 junction,
and the 945-bp fragment of thenative ileS genewere submitted to the
Texas A&M Gene Technologies Laboratory for sequencing. Resul-
tant sequences were compared to sequences in GenBank (JX186508,
JX186509, JX186511, JX186512, JX186513, and JX186514) using
MEGA5.1 software (6, 12).
Of the 581 isolates tested, only one isolate was resistant to
mupirocin. The isolate, 39-045, was originally cultured from the
nares of a healthy, 1-year-old, castrated, male, Bernese mountain
dog presenting for an orthopedic evaluation. This isolate was pan-
susceptible to all antimicrobials tested using the COMPAN2F
drug panel and negative for the presence of themecA gene via PCR
analysis. The prevalence of mupirocin resistance in dogs without
clinical staphylococcal infections that presented for elective or-
thopedic procedures was 1 in 129, or 0.8%. An additional 194 S.
pseudintermedius isolates were collected from 158 dogs with clin-
ical infections during the same period of collection (22 September
2010 to 8 February 2012), resulting in a total of 372 S. pseudinter-
medius isolates from 287 dogs. The prevalence of mupirocin-re-
sistant S. pseudintermedius in dogs cultured between 22 Septem-
ber 2010 and 8 February 2012was therefore 1 in 287 dogs, or 0.3%.
The mupirocin-resistant isolate was analyzed for the presence
of high-level mupirocin resistance by plasmid DNA isolation fol-
lowed by PCR amplification of two different regions of the plas-
mid-borne ileS2 gene. The presence of a 458-bp band with mupA
and mupB primers and a 237-bp band with M1 and M2 primers
indicates that the isolate contains the ileS2 gene (Fig. 1).
To further determine the structural type of the plasmid, PCR
for the IS257-ileS2 spacer regions was performed according to a
previously published molecular classification system (11). The
fragments are similar to the amplification for structural group S2
ileS2 plasmids found in S. aureus pattern II, with bands sized be-
tween 1,000 bp and 1,650 bp for primers ileS2-3= and IS257F and
between 2,000 and 3,054 bp for primers IS257R and ileS2-5= (Fig.
2). This structural group is similar to the structure previously
reported for the plasmid-borne ileS2 gene identified in S. pseud-
intermedius isolated froma dogwith pyoderma inCroatia (6). The
resultant PCR products were sequenced and compared to the pre-
viously published ileS2 sequences from S. pseudintermedius,
JX186508 and JX186509 (6). Sequences from this study were de-
posited in GenBank as KJ000545, KJ000546, and KJ000547. Com-
parison of JX186509 with KJ000545 using MEGA5.1 software in-
dicated 99% similarity between the two sequences. Comparison of
JX186508 with KJ000546 and KJ000547 indicated 100% and 99%
similarity between the sequences, respectively.
To determine whether isolate 39-045 had both an ileS muta-
tion and the ileS2 plasmid simultaneously, PCR amplification of
the chromosomal ileS gene was also performed using previously
FIG 1 Detection of ileS2 using PCR. Lanes 1 to 3 include PCR products am-
plified with mupA and mupB primers (9). Lanes 4 to 6 include PCR products
amplified with M1 and M2 primers (10). The molecular size marker used in
lanes 1 and 8 was a 100-bpDNA ladder (Invitrogen, Grand Island, NY). Num-
bers at left aremolecular sizes in bp. Template DNA used for PCRwas plasmid
DNA from isolate 39-045 (lanes 2 and 5) or genomic DNA from ATCC 29213
(lanes 3 and 6). Water was substituted for DNA in lanes 4 and 7.
TABLE 1 Primers used in this study
Target gene Primer Sequence (5= to 3=) Reference
ileS2 mupA TATATTATGCGATGGAAGGTTGG 9
mupB AATAAAATCAGCTGGAAAGTGTTG 9
M1 GTTTATCTTCTGATGCTGAG 10
M2 CCCCAGTTACACCGATATAA 10
IS257-ileS2 junctions IS257F GGCATGGCGAAAATCCGTAG 11
IS257R TGGCGTATTGATGAGACGTACATC 11
ileS2-3= TCGGTGTAACTGGGGAATTA 11
ileS2-5= CCATGTCAACCCAGTATCC 11
ileS ileS-F1 CGTGACCGTGGCGAATGGGT 6
ileS-R1 GTATGCGGAATGATTGGCG 6
mecA mecA F CTCAGGTACTGCTATCCACC 7
mecA R CACTTGGTATATCTTCACC 7
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published primers (6). The resultant 945-bp product was se-
quenced and analyzed usingMEGA5.1 software, and the sequence
was deposited in GenBank as KJ000544. Analysis indicated a 99%
similarity between isolate 39-045 and the previously published
sequences of the S. pseudintermedius chromosomal ileS gene:
JX186511, JX186512, JX186513, and JX186514 (6).
In summary, this study found that the prevalence ofmupirocin
resistance in S. pseudintermedius isolated from dogs was 0.3% (1/
287) or 0.8% (1/129) in healthy dogs without active, clinical
staphylococcal infections. While no mupirocin-resistant isolates
were found in our collection of isolates from dogs with clinical
disease, the presence of plasmid-mediatedmupirocin resistance is
of concern as previous work has demonstrated that mupirocin
resistance can be transmitted fromone species of Staphylococcus to
another in vivo (13). Increased rates of methicillin resistance and
multidrug resistance in S. pseudintermedius and approval ofmupi-
rocin for use in dogs have made mupirocin an attractive alterna-
tive for topical use in canine pyoderma (2). This could result in
increased mupirocin resistance in S. pseudintermedius over time.
Although our study found only one mupirocin-resistant S. pseud-
intermedius isolate, 36.5% of U.S. households own a dog (14), and
there is the potential for transmission of mupirocin resistance
from canine isolates of S. pseudintermedius to human isolates of S.
aureus or vice versa. This could have implications for public
health. For these reasons, mupirocin resistance should be moni-
tored and carefully considered before mupirocin is used in canine
patients.
Nucleotide sequence accession numbers. Sequences from
this study were deposited in GenBank as KJ000544, KJ000545,
KJ000546, and KJ000547.
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FIG 2 Detection of the ileS2-IS257 junctions in isolate 39-045 using ileS2-5=,
IS257F, ileS2-3=, and IS257R primers (11). Primer pairs for each reaction were
as follows: PCR 1, ileS2-5= and IS257F; PCR 2, ileS2-5= and IS257R; PCR 3,
ileS2-3= and IS257F; and PCR 4, ileS2-3= and IS257R. Lanes 2, 6, and 10 are
products from PCR 1; lanes 3, 7, and 11 are products from PCR 2; lanes 4, 8,
and 12 are products from PCR 3; lanes 5, 9, and 13 are products from PCR 4;
and lanes 1 and 14 are a 1-kb DNA ladder (Invitrogen, Grand Island, NY).
Template DNA in lanes 2 to 5 is plasmid DNA from isolate 39-045. Template
DNA in lanes 6 to 9 is genomic DNA from ATCC 29213 used as a negative
control. In lanes 10 to 13, water was substituted for templateDNAas a negative
control. No positive controls were available. Numbers at left are sizes in bases.
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